Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 888.

https://doi.org/10.1182/blood-2025-888

Published: 2025

Journal Articles

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy Abramson, Jacob Soumerai, Maria Martinez-Lage, Julie Haydu, Ganesh Shankar, Chirayu Patel, Bryan D. Choi, Jeffrey Barnes, Areej El-Jawahri, Ephraim Hochberg, Patrick Connor Johnson, Wolfgang Wick, Marcela Maus, Yi-Bin Chen, Matthew Frigault, Jorg Dietrich

Blood (2025) 146 (Supplement 1): 5493.

https://doi.org/10.1182/blood-2025-5493

Published: 2025

Journal Articles

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Blood (2025) 146 (Supplement 1): 3569.

https://doi.org/10.1182/blood-2025-3569

Published: 2025

Journal Articles

The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes

Jessica Nino De Rivera, Shruthi Venkatachalam, Kyle Karpinski, Elane Kim, Anna Barata, Meaghan Ekstrom, Richard Newcomb, Trisha Rahman, Nova Hodge, Lauren DeMarco, Matthew Frigault, Areej El-Jawahri, Patrick Connor Johnson

Blood (2025) 146 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2025-4544

Published: 2025

Journal Articles

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis

Patrick Connor Johnson, Evelyn Guo, Guihua Zhang, Tongsheng Wang, Vardhaman Patel, Alex Mutebi, Mohammad Atiya, Jon Ukropec, Anthony Wang, Signe Vindeløv, Justin Darrah

Blood (2025) 146 (Supplement 1): 7251.

https://doi.org/10.1182/blood-2025-7251

Published: 2025

Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Blood (2025) 146 (Supplement 1): 245.

https://doi.org/10.1182/blood-2025-245

Published: 2025

Journal Articles

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy

Blood (2025) 146 (Supplement 1): 243.

https://doi.org/10.1182/blood-2025-243

Published: 2025

Journal Articles

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Blood (2025) 146 (16): 1902–1913.

https://doi.org/10.1182/blood.2025028964

Published: 2025

Includes: Supplemental data

Journal Articles

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood (2025) 145 (5): 497–507.

https://doi.org/10.1182/blood.2024025563

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Michael Wang, Patrick Connor Johnson, Salim Yazji, Yisrael Katz, Angela Pietrofeso, James Robinson, Matthew Mei, Matthew J. Frigault, James B. Breitmeyer, Caron A. Jacobson

Blood (2024) 144 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2024-200998

Published: 2024

Journal Articles

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Elisa Ten Hacken, Johan Gustafsson, Chiara Tomasoni, Gabriela Brunsting Hoffmann, Kayla Cruz, Wesley S Lu, Shuqiang Li, Nicholas Haradhvala, Connor Johnson, Stephanie Deng, Xia Bu, Donna S. Neuberg, Othman Al-Sawaf, Barbara F. Eichhorst, Clare Sun, Erin M. Parry, Gordon J. Freeman, Gad Getz, Catherine J. Wu

Blood (2024) 144 (Supplement 1): 761.

https://doi.org/10.1182/blood-2024-201006

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

Patrick Connor Johnson, Richard Newcomb, Jeremy S. Abramson, Ann S. LaCasce, Julia Rice, Daniel Yang, Bridget Coffey, Sruthi K. Venkatachalam, Netana H. Markovitz, Emilia Kaslow-Zieve, Oreofe O. Odejide, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 400.

https://doi.org/10.1182/blood-2024-205279

Published: 2024

Journal Articles

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Anna Barata, Richard Newcomb, Patrick Connor Johnson, Ella Caruso, Porsha Lark, Emelia J. Farnam, Thomas W. LeBlanc, Stephanie J. Lee, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2024-202065

Published: 2024

Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz

Blood (2024) 144 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2024-205697

Published: 2024

Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 738.

https://doi.org/10.1182/blood-2023-180069

Published: 2023

Journal Articles

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Netana Markovitz, Oreofe O. Odejide, Areej El-Jawahri, Patrick Connor Johnson

Blood (2023) 142 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2023-187708

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Polyfunctional Effector PD-1 + CD8 + T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only